427 related articles for article (PubMed ID: 8174107)
21. Exclusion of the Wilms tumour gene (WT1) promoter as a site of frequent mutation in Wilms tumour.
Grubb GR; Yun K; Reeve AE; Eccles MR
Oncogene; 1995 Apr; 10(8):1677-81. PubMed ID: 7731725
[TBL] [Abstract][Full Text] [Related]
22. Genetics of Wilms' tumor.
Coppes MJ; Egeler RM
Semin Urol Oncol; 1999 Feb; 17(1):2-10. PubMed ID: 10073400
[TBL] [Abstract][Full Text] [Related]
23. Frequency and heritability of WT1 mutations in nonsyndromic Wilms' tumor patients: a UK Children's Cancer Study Group Study.
Little SE; Hanks SP; King-Underwood L; Jones C; Rapley EA; Rahman N; Pritchard-Jones K
J Clin Oncol; 2004 Oct; 22(20):4140-6. PubMed ID: 15483024
[TBL] [Abstract][Full Text] [Related]
24. [Four new cases with WT1 gene mutations in Chinese patients with Wilms' tumor].
Jiang YP; Shen Y; Sun N; Wang H
Zhonghua Er Ke Za Zhi; 2009 Oct; 47(10):762-6. PubMed ID: 20021811
[TBL] [Abstract][Full Text] [Related]
25. Germline WT1 mutations in Wilms' tumor patients: preliminary results.
Li FP; Breslow NE; Morgan JM; Ghahremani M; Miller GA; Grundy PE; Green DM; Diller LR; Pelletier J
Med Pediatr Oncol; 1996 Nov; 27(5):404-7. PubMed ID: 8827066
[TBL] [Abstract][Full Text] [Related]
26. Low incidence of point mutations detected in the p53 tumor suppressor gene from chemically induced rat renal mesenchymal tumors.
Weghorst CM; Dragnev KH; Buzard GS; Thorne KL; Vandeborne GF; Vincent KA; Rice JM
Cancer Res; 1994 Jan; 54(1):215-9. PubMed ID: 8261441
[TBL] [Abstract][Full Text] [Related]
27. Mutation of the p53 gene in neuroblastoma and its relationship with N-myc amplification.
Imamura J; Bartram CR; Berthold F; Harms D; Nakamura H; Koeffler HP
Cancer Res; 1993 Sep; 53(17):4053-8. PubMed ID: 8358734
[TBL] [Abstract][Full Text] [Related]
28. Identification and analysis of mutations in WTX and WT1 genes in peripheral blood and tumor tissue of children with Wilms' tumor.
Wang H; Shen Y; Sun N; Jiang YP; Li ML; Sun L
Chin Med J (Engl); 2012 May; 125(10):1733-9. PubMed ID: 22800892
[TBL] [Abstract][Full Text] [Related]
29. Myogenesis in Wilms' tumors is associated with mutations of the WT1 gene and activation of Bcl-2 and the Wnt signaling pathway.
Fukuzawa R; Heathcott RW; Sano M; Morison IM; Yun K; Reeve AE
Pediatr Dev Pathol; 2004; 7(2):125-37. PubMed ID: 14994125
[TBL] [Abstract][Full Text] [Related]
30. p53, Ki-ras, and DNA ploidy in human pancreatic ductal adenocarcinomas.
Weyrer K; Feichtinger H; Haun M; Weiss G; Ofner D; Weger AR; Umlauft F; Grünewald K
Lab Invest; 1996 Jan; 74(1):279-89. PubMed ID: 8569192
[TBL] [Abstract][Full Text] [Related]
31. RNA polymerase chain reaction detects different levels of four alternatively spliced WT1 transcripts in Wilms' tumors.
Brenner B; Wildhardt G; Schneider S; Royer-Pokora B
Oncogene; 1992 Jul; 7(7):1431-3. PubMed ID: 1320246
[TBL] [Abstract][Full Text] [Related]
32. Altered trans-activational properties of a mutated WT1 gene product in a WAGR-associated Wilms' tumor.
Park S; Tomlinson G; Nisen P; Haber DA
Cancer Res; 1993 Oct; 53(20):4757-60. PubMed ID: 8402654
[TBL] [Abstract][Full Text] [Related]
33. Mutation and overexpression of the p53 tumor suppressor gene frequently occurs in uterine and ovarian sarcomas.
Liu FS; Kohler MF; Marks JR; Bast RC; Boyd J; Berchuck A
Obstet Gynecol; 1994 Jan; 83(1):118-24. PubMed ID: 8272291
[TBL] [Abstract][Full Text] [Related]
34. Role of the WT1 gene in Wilms' tumour.
Haber DA; Housman DE
Cancer Surv; 1992; 12():105-17. PubMed ID: 1322241
[TBL] [Abstract][Full Text] [Related]
35. Upregulation of c-MYC in WT1-mutant tumors: assessment of WT1 putative transcriptional targets using cDNA microarray expression profiling of genetically defined Wilms' tumors.
Udtha M; Lee SJ; Alam R; Coombes K; Huff V
Oncogene; 2003 Jun; 22(24):3821-6. PubMed ID: 12802290
[TBL] [Abstract][Full Text] [Related]
36. High frequency and heterogeneous distribution of p53 mutations in aflatoxin B1-induced mouse lung tumors.
Tam AS; Foley JF; Devereux TR; Maronpot RR; Massey TE
Cancer Res; 1999 Aug; 59(15):3634-40. PubMed ID: 10446974
[TBL] [Abstract][Full Text] [Related]
37. A novel WT1 gene mutation associated with wilms' tumor and congenital male genitourinary malformation.
Sakamoto J; Takata A; Fukuzawa R; Kikuchi H; Sugiyama M; Kanamori Y; Hashizume K; Hata JI
Pediatr Res; 2001 Sep; 50(3):337-44. PubMed ID: 11518820
[TBL] [Abstract][Full Text] [Related]
38. Anaplasia and drug selection-independent overexpression of the multidrug resistance gene, MDR1, in Wilms' tumor.
Re GG; Willingham MC; el Bahtimi R; Brownlee NA; Hazen-Martin DJ; Garvin AJ
Mod Pathol; 1997 Feb; 10(2):129-36. PubMed ID: 9127318
[TBL] [Abstract][Full Text] [Related]
39. p53 Immunostaining guided laser capture microdissection (p53-LCM) defines the presence of p53 gene mutations in focal regions of primary prostate cancer positive for p53 protein.
Griewe GL; Dean RC; Zhang W; Young D; Sesterhenn IA; Shanmugam N; McLeod DG; Moul JW; Srivastava S
Prostate Cancer Prostatic Dis; 2003; 6(4):281-5. PubMed ID: 14663467
[TBL] [Abstract][Full Text] [Related]
40. Mutations of the p53 gene are involved in Ewing's sarcomas but not in neuroblastomas.
Komuro H; Hayashi Y; Kawamura M; Hayashi K; Kaneko Y; Kamoshita S; Hanada R; Yamamoto K; Hongo T; Yamada M
Cancer Res; 1993 Nov; 53(21):5284-8. PubMed ID: 8221663
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]